These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 643030)

  • 21. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies.
    Lee SW; Sullenger BA
    Nat Biotechnol; 1997 Jan; 15(1):41-5. PubMed ID: 9035104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis.
    Mittag T; Kornfeld P; Tormay A; Woo C
    N Engl J Med; 1976 Mar; 294(13):691-4. PubMed ID: 1250280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of acetylcholine receptor antibodies in myasthenia gravis.
    Appel SH; Elias SB; Chauvin P
    Fed Proc; 1979 Sep; 38(10):2381-5. PubMed ID: 478014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of myasthenic immunoglobulins and cholinergic agonists on acetylcholine receptors of rat myotubes.
    Ashizawa T; Elias SB; Appel SH
    Ann Neurol; 1982 Jan; 11(1):22-7. PubMed ID: 6277235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis.
    Mittag T; Massa T; Kornfeld P; Papatestas A; Bender A; Genkins G
    Muscle Nerve; 1981; 4(1):16-25. PubMed ID: 6164920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acetylcholine receptor in myasthenia gravis: increased affinity for alpha-bungarotoxin.
    Elias SB; Appel SH
    Ann Neurol; 1978 Sep; 4(3):250-2. PubMed ID: 718136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.
    Kao I; Drachman DB
    Science; 1977 Apr; 196(4289):527-9. PubMed ID: 850793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetylcholine receptor antibody synthesis in lymphocyte cultures.
    McLachlan SM; Nicholson LV; Venables G; Mastalgia FL; Bates D; Smith BR; Hall R
    J Clin Lab Immunol; 1981 May; 5(3):137-42. PubMed ID: 7241564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM.
    Yamamoto T; Vincent A; Ciulla TA; Lang B; Johnston I; Newsom-Davis J
    Ann Neurol; 1991 Oct; 30(4):550-7. PubMed ID: 1665051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
    Tzartos SJ; Sophianos D; Efthimiadis A
    J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A.
    Szpirt W; Somnier F; Nielsen FC; Rødgaard A
    Life Support Syst; 1985; 3 Suppl 1():351-5. PubMed ID: 3916613
    [No Abstract]   [Full Text] [Related]  

  • 32. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H; Kokla A; Tzartos SJ
    Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture.
    Sideris S; Lagoumintzis G; Kordas G; Kostelidou K; Sotiriadis A; Poulas K; Tzartos SJ
    J Neuroimmunol; 2007 Sep; 189(1-2):111-7. PubMed ID: 17617475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pathogenic antibodies in myasthenia gravis].
    Motomura M
    Brain Nerve; 2010 Apr; 62(4):411-8. PubMed ID: 20420182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Degradation of acetylcholine receptor in diaphragms of rats with experimental autoimmune myasthenia gravis.
    Merlie JP; Heinemann S; Einarson B; Lindstrom JM
    J Biol Chem; 1979 Jul; 254(14):6328-32. PubMed ID: 447717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acetylcholine receptor antibodies in the diagnosis of human and experimental myasthenia gravis.
    Heilbronn E; Lefvert AK; Stålberg E
    Muscle Nerve; 1978; 1(5):427-31. PubMed ID: 263985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
    Kuncl RW; Drachman DB; Adams R; Lehar M
    J Pharmacol Exp Ther; 1993 Nov; 267(2):582-9. PubMed ID: 8246131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of acetylcholine receptor loss in myasthenia gravis.
    Drachman DB; Adams RN; Stanley EF; Pestronk A
    J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):601-10. PubMed ID: 6249894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.